KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares OutstandingShares Outstanding
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Depreciation & Amortization (2016 - 2026)

CRISPR Therapeutics AG (CRSP) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $91.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 25.99% to $91.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $91.1 million through Dec 2025, up 25.99% year-over-year, with the annual reading at $91.1 million for FY2025, 25.99% up from the prior year.
  • Accumulated Depreciation & Amortization hit $91.1 million in Q4 2025 for CRISPR Therapeutics AG, up from $85.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $91.1 million in Q4 2025 to a low of $23.9 million in Q1 2021.
  • Historically, Accumulated Depreciation & Amortization has averaged $53.0 million across 5 years, with a median of $49.8 million in 2022.
  • Biggest YoY gain for Accumulated Depreciation & Amortization was 85.67% in 2022; the steepest drop was 14.8% in 2022.
  • Year by year, Accumulated Depreciation & Amortization stood at $37.8 million in 2021, then dropped by 10.51% to $33.8 million in 2022, then soared by 57.94% to $53.4 million in 2023, then surged by 35.26% to $72.3 million in 2024, then rose by 25.99% to $91.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for CRSP at $91.1 million in Q4 2025, $85.6 million in Q3 2025, and $81.6 million in Q2 2025.